285 related articles for article (PubMed ID: 23697367)
21. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
22. Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
Spentzos D; Levine DA; Kolia S; Otu H; Boyd J; Libermann TA; Cannistra SA
J Clin Oncol; 2005 Nov; 23(31):7911-8. PubMed ID: 16204010
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms and Therapeutic Targets of microRNA-associated Chemoresistance in Epithelial Ovarian Cancer.
Zhang L; Nadeem L; Connor K; Xu G
Curr Cancer Drug Targets; 2016; 16(5):429-41. PubMed ID: 27040353
[TBL] [Abstract][Full Text] [Related]
24. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.
Ghosh S; Albitar L; LeBaron R; Welch WR; Samimi G; Birrer MJ; Berkowitz RS; Mok SC
Gynecol Oncol; 2010 Oct; 119(1):114-20. PubMed ID: 20619446
[TBL] [Abstract][Full Text] [Related]
26. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization.
Zhao Z; Shuang T; Gao Y; Lu F; Zhang J; He W; Qu L; Chen B; Hao Q
Cancer Lett; 2022 Apr; 530():45-58. PubMed ID: 35051533
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.
Ye G; Fu G; Cui S; Zhao S; Bernaudo S; Bai Y; Ding Y; Zhang Y; Yang BB; Peng C
J Cell Sci; 2011 Feb; 124(Pt 3):359-68. PubMed ID: 21224400
[TBL] [Abstract][Full Text] [Related]
32. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
33. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
34. CXCL11 mediates TWIST1-induced angiogenesis in epithelial ovarian cancer.
Koo YJ; Kim TJ; Min KJ; So KA; Jung US; Hong JH
Tumour Biol; 2017 May; 39(5):1010428317706226. PubMed ID: 28488542
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
Weiner-Gorzel K; Dempsey E; Milewska M; McGoldrick A; Toh V; Walsh A; Lindsay S; Gubbins L; Cannon A; Sharpe D; O'Sullivan J; Murphy M; Madden SF; Kell M; McCann A; Furlong F
Cancer Med; 2015 May; 4(5):745-58. PubMed ID: 25684390
[TBL] [Abstract][Full Text] [Related]
36. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer.
Pei ML; Zhao ZX; Shuang T
J Ovarian Res; 2020 Dec; 13(1):144. PubMed ID: 33302997
[TBL] [Abstract][Full Text] [Related]
39. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays.
Martoglio AM; Tom BD; Starkey M; Corps AN; Charnock-Jones DS; Smith SK
Mol Med; 2000 Sep; 6(9):750-65. PubMed ID: 11071270
[TBL] [Abstract][Full Text] [Related]
40. The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer.
Zhou Y; Wang M; Wu J; Jie Z; Chang S; Shuang T
J Ovarian Res; 2015 Apr; 8():23. PubMed ID: 25887170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
